US Position on LDC Pharmaceutical Extension of TRIPS Transition Period

Health GAP, Public Citizen, KEI, MSF, and Oxfam America sent this letter to the United States Trade Representative and US Patent and Trade Mark Office demanding that the US disclose its position on WTO Least Developed Country Members request that their extension of responsibilities under the TRIPS agreement with respect to medicines be extended unconditionally until they are no longer LDCs.  The letter also criticizes several positions that the US is likely to take.  Unlike the US, the European Commission has publicly announced its support for the LDC request.

Donate Stay Connected